How extra-chromosomal DNA (ecDNA) helps tumors grow and resist treatment
Quantitative modeling of extrachromosomal DNA (ecDNA) evolution in tumors
This project builds computer models and lab tools to track how ecDNA lets cancer cells change and survive, with the aim of helping people whose tumors are driven by ecDNA.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11457122 on NIH RePORTER |
What this research studies
You would see researchers combining computer modeling with lab experiments to follow how ecDNA (extra-chromosomal DNA) changes inside tumor cells over time and under stress. They will analyze tumor samples and cell lines, use CRISPR-based screens to pinpoint genes on ecDNA that drive growth or drug resistance, and develop methods to map ecDNA diversity across many tumors. The team plans to link these lab and computational findings to real patient tumor profiles so future treatments can be targeted more effectively. This is primarily lab and data work and does not offer immediate treatment, but it could shape future clinical options.
Who could benefit from this research
Good fit: People with cancers known or suspected to contain ecDNA—often aggressive tumors where ecDNA has been detected—would be most relevant to this research.
Not a fit: Patients whose cancers do not involve ecDNA or those looking for immediate treatment options may not benefit directly from this lab-focused project.
Why it matters
Potential benefit: If successful, the work could lead to tests that predict tumor evolution and new targets to overcome drug resistance in cancers with ecDNA.
How similar studies have performed: Research on ecDNA is relatively new: lab studies have linked ecDNA to growth and resistance, but combining quantitative modeling with CRISPR screens is a novel and emerging approach.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Jones, Matthew Gregory — Massachusetts Institute of Technology
- Study coordinator: Jones, Matthew Gregory
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.